{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T02:24:01Z","timestamp":1794191041139,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J08254"],"award-info":[{"award-number":["2024J08254"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022GGA008"],"award-info":[{"award-number":["2022GGA008"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["23ZYCGSN00960"],"award-info":[{"award-number":["23ZYCGSN00960"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10637-026-01633-z","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:10:19Z","timestamp":1787793019000},"page":"414-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Wenjun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengrang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weike","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"3","key":"1633_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL et al (2020) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"1633_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041726","author":"C Romei","year":"2021","unstructured":"Romei C, Elisei R (2021) A narrative review of genetic alterations in primary thyroid epithelial cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22041726","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1633_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0958-x","volume":"14","author":"AK Murugan","year":"2016","unstructured":"Murugan AK, Qasem E, Al-Hindi H, Shi Y, Alzahrani AS (2016) Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. J Transl Med 14(1):204","journal-title":"J Transl Med"},{"issue":"9","key":"1633_CR4","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1210\/jc.2006-1006","volume":"91","author":"Z Zhu","year":"2006","unstructured":"Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE (2006) Prevalence of RET\/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91(9):3603\u20133610","journal-title":"J Clin Endocrinol Metab"},{"key":"1633_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090698","author":"R Elisei","year":"2019","unstructured":"Elisei R, Tacito A, Ramone T et al (2019) Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes. https:\/\/doi.org\/10.3390\/genes10090698","journal-title":"Genes"},{"key":"1633_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215567","author":"S Ulisse","year":"2021","unstructured":"Ulisse S, Baldini E, Lauro A et al (2021) Papillary thyroid cancer prognosis: an evolving field. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215567","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1633_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00795-019-00217-6","volume":"52","author":"S Kure","year":"2019","unstructured":"Kure S, Wada R, Naito Z (2019) Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma. Med Mol Morphol 52(4):181\u2013186","journal-title":"Med Mol Morphol"},{"key":"1633_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050333","author":"A Ieni","year":"2021","unstructured":"Ieni A, Vita R, Pizzimenti C, Benvenga S, Tuccari G (2021) Intratumoral heterogeneity in differentiated thyroid tumors: an intriguing reappraisal in the era of personalized medicine. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11050333","journal-title":"J Pers Med"},{"key":"1633_CR9","doi-asserted-by":"crossref","unstructured":"Yip L, Nikiforova MN, Yoo JY, et al (2015) Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg 262(3) 519\u201325; discussion 524\u20135","DOI":"10.1097\/SLA.0000000000001420"},{"issue":"7","key":"1633_CR10","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/ERC-21-0368","volume":"29","author":"A Angelousi","year":"2022","unstructured":"Angelousi A, Hayes AR, Chatzellis E, Kaltsas GA, Grossman AB (2022) Metastatic medullary thyroid carcinoma: a new way forward. Endocr Relat Cancer 29(7):R85\u2013R103","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1633_CR11","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","volume":"109","author":"W Zhang","year":"2024","unstructured":"Zhang W, Lin S, Wang Z, Zhang W, Xing M (2024) Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targeting in thyroid cancer. J Clin Endocrinol Metab 109(12):3166\u20133175","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1633_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134\u2013141","journal-title":"J Clin Oncol"},{"issue":"29","key":"1633_CR13","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639\u20133646","journal-title":"J Clin Oncol"},{"issue":"9","key":"1633_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383(9):825\u2013835","journal-title":"N Engl J Med"},{"issue":"8","key":"1633_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Hu MI, Wirth LJ et al (2021) Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol 9(8):491\u2013501","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1633_CR16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210390","author":"R Raman","year":"2022","unstructured":"Raman R, Villefranc JA, Ullmann TM et al (2022) Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20210390","journal-title":"J Exp Med"},{"issue":"43","key":"1633_CR17","doi-asserted-by":"publisher","first-page":"41677","DOI":"10.1074\/jbc.M306461200","volume":"278","author":"T Araki","year":"2003","unstructured":"Araki T, Nawa H, Neel BG (2003) Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 278(43):41677\u201341684","journal-title":"J Biol Chem"},{"issue":"1","key":"1633_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0659-z","volume":"18","author":"F Matalkah","year":"2016","unstructured":"Matalkah F, Martin E, Zhao H, Agazie YM (2016) SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Res 18(1):2","journal-title":"Breast Cancer Res"},{"key":"1633_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9859","volume":"6","author":"S Bunda","year":"2015","unstructured":"Bunda S, Burrell K, Heir P et al (2015) Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun 6:8859","journal-title":"Nat Commun"},{"issue":"1","key":"1633_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/hep.30989","volume":"72","author":"C Leung","year":"2020","unstructured":"Leung C, Tong M, Chung K et al (2020) Overriding adaptive resistance to sorafenib through combination therapy with Src homology 2 domain-containing phosphatase 2 blockade in hepatocellular carcinoma. Hepatology 72(1):155\u2013168","journal-title":"Hepatology"},{"issue":"49","key":"1633_CR21","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1038\/s41388-020-01488-5","volume":"39","author":"H Chen","year":"2020","unstructured":"Chen H, Libring S, Ruddraraju KV et al (2020) SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene 39(49):7166\u20137180","journal-title":"Oncogene"},{"issue":"4","key":"1633_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.4497","volume":"24","author":"L Dardaei","year":"2018","unstructured":"Dardaei L, Wang HQ, Singh M et al (2018) SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med 24(4):512\u2013517","journal-title":"Nat Med"},{"issue":"9","key":"1633_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1158\/1535-7163.MCT-20-0965","volume":"20","author":"H Kano","year":"2021","unstructured":"Kano H, Ichihara E, Watanabe H et al (2021) SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-na\u00efve ALK-, ROS1-, or EGFR-altered non-small cell lung cancer. Mol Cancer Ther 20(9):1653\u20131662","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"1633_CR24","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","volume":"80","author":"Y Sun","year":"2020","unstructured":"Sun Y, Meyers BA, Czako B et al (2020) Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib. Cancer Res 80(21):4840\u20134853","journal-title":"Cancer Res"},{"issue":"7610","key":"1633_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"YN Chen","year":"2016","unstructured":"Chen YN, LaMarche MJ, Chan HM et al (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535(7610):148\u2013152","journal-title":"Nature"},{"issue":"7","key":"1633_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Gainor JF, Rahal R et al (2018) Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov 8(7):836\u2013849","journal-title":"Cancer Discov"},{"issue":"8","key":"1633_CR27","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Velcheti V, Tuch BB et al (2018) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29(8):1869\u20131876","journal-title":"Ann Oncol"},{"issue":"12","key":"1633_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550","journal-title":"Genome Biol"},{"issue":"5","key":"1633_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY (2012) ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284\u2013287","journal-title":"OMICS"},{"issue":"43","key":"1633_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1633_CR31","first-page":"247","volume":"12","author":"J Zhi","year":"2022","unstructured":"Zhi J, Yi J, Hou X et al (2022) Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor. Am J Cancer Res 12(1):247\u2013264","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1633_CR32","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","volume":"13","author":"EY Rosen","year":"2022","unstructured":"Rosen EY, Won HH, Zheng Y et al (2022) The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun 13(1):1450","journal-title":"Nat Commun"},{"issue":"12","key":"1633_CR33","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","volume":"7","author":"KZ Thein","year":"2021","unstructured":"Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V (2021) Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 7(12):1074\u20131088","journal-title":"Trends Cancer"},{"key":"1633_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932353","volume":"12","author":"AT Regua","year":"2022","unstructured":"Regua AT, Najjar M, Lo HW (2022) RET signaling pathway and RET inhibitors in human cancer. Front Oncol 12:932353","journal-title":"Front Oncol"},{"issue":"30","key":"1633_CR35","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1038\/sj.onc.1203688","volume":"19","author":"DH Arlt","year":"2000","unstructured":"Arlt DH, Baur B, Wagner B, H\u00f6ppner W (2000) A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation. Oncogene 19(30):3445\u20133448","journal-title":"Oncogene"},{"issue":"6","key":"1633_CR36","first-page":"1207","volume":"11","author":"G Viglietto","year":"1995","unstructured":"Viglietto G, Chiappetta G, Martinez-Tello FJ et al (1995) RET\/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11(6):1207\u20131210","journal-title":"Oncogene"},{"issue":"4","key":"1633_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.09.011","volume":"36","author":"RC Doebele","year":"2019","unstructured":"Doebele RC (2019) Acquired resistance is oncogene and drug agnostic. Cancer Cell 36(4):347\u2013349","journal-title":"Cancer Cell"},{"issue":"1","key":"1633_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M et al (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19(1):58\u201371","journal-title":"Cancer Cell"},{"issue":"7","key":"1633_CR39","first-page":"2609","volume":"118","author":"M Guix","year":"2008","unstructured":"Guix M, Faber AC, Wang SE et al (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118(7):2609\u20132619","journal-title":"J Clin Invest"},{"issue":"1","key":"1633_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","volume":"17","author":"AB Turke","year":"2010","unstructured":"Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77\u201388","journal-title":"Cancer Cell"},{"issue":"5827","key":"1633_CR41","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039\u20131043","journal-title":"Science"},{"issue":"9","key":"1633_CR42","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2767-9764.CRC-21-0137","volume":"2","author":"R Kurupi","year":"2022","unstructured":"Kurupi R, Floros KV, Jacob S et al (2022) Pharmacologic inhibition of SHP2 blocks both PI3K and MEK signaling in low-epiregulin HNSCC via GAB1. Cancer Res Commun 2(9):1061\u20131074","journal-title":"Cancer Res Commun"},{"issue":"1","key":"1633_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","volume":"26","author":"TA Ahmed","year":"2019","unstructured":"Ahmed TA, Adamopoulos C, Karoulia Z et al (2019) SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors. Cell Rep 26(1):65-78.e5","journal-title":"Cell Rep"},{"issue":"9","key":"1633_CR44","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols RJ, Haderk F, Stahlhut C et al (2018) RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol 20(9):1064\u20131073","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1633_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","volume":"27","author":"EY Rosen","year":"2021","unstructured":"Rosen EY, Johnson ML, Clifford SE et al (2021) Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 27(1):34\u201342","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1633_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12038-017-9667-8","volume":"42","author":"R Kumari","year":"2017","unstructured":"Kumari R, Chouhan S, Singh S, Chhipa RR, Ajay AK, Bhat MK (2017) Constitutively activated ERK sensitizes cancer cells to doxorubicin: involvement of p53-EGFR-ERK pathway. J Biosci 42(1):31\u201341","journal-title":"J Biosci"},{"issue":"3","key":"1633_CR47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/15548627.2022.2103961","volume":"19","author":"S Chouhan","year":"2023","unstructured":"Chouhan S, Sawant M, Weimholt C et al (2023) TNK2\/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability. Autophagy 19(3):1000\u20131025","journal-title":"Autophagy"},{"issue":"1","key":"1633_CR48","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1038\/s41467-024-49978-4","volume":"15","author":"S Chouhan","year":"2024","unstructured":"Chouhan S, Sridaran D, Weimholt C et al (2024) SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis. Nat Commun 15(1):5629","journal-title":"Nat Commun"},{"issue":"1","key":"1633_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010183","volume":"26","author":"S Chouhan","year":"2025","unstructured":"Chouhan S, Muhammad N, Usmani D et al (2025) Molecular sentinels: unveiling the role of sirtuins in prostate cancer progression. Int J Mol Sci 26(1):183","journal-title":"Int J Mol Sci"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01633-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01633-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01633-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T02:08:48Z","timestamp":1794190128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01633-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1633"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01633-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments comply with ethical standards, and animal protocols were approved by the Tianjin Medical University Cancer Institute Ethics Committee. In this study, the CO2 asphyxia method was used to euthanize the experimental animals. The CO\u2082 gas was preheated to room temperature and then introduced at a uniform flow rate. After the mice died, ventilation was continued for 2\u00a0min. Before dissection, the toes were kneaded and pressed for a second confirmation. This approach strictly follows the Guidelines of the American Veterinary Medical Association (AVMA) for the Euthanasia of Animals (2020).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All author consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}